Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: a systematic review with meta-analysis
A partir d'une revue systématique de la littérature publiée jusqu'en août 2023 (126 études), cette méta-analyse évalue l'intérêt, du point de vue de la survie, d'ajouter une radiothérapie à une immunothérapie ou à un traitement ciblé pour des métastases cérébrales ayant pour origine un mélanome
Background: Patients with melanoma brain metastases are now frequently treated with immunotherapy(IMT) or targeted therapy (TT). The aim of this systematic review was to determine relative survival outcomes after combining radiotherapy (RT) with IMT or TT.
Methods: 126 studies were identified by searching Medline, Embase and Cochrane CENTRAL(to 7Aug 2023).
Results: Multivariable analyses showed that the risk of death was reduced by 30% for combined stereotactic radiosurgery (SRS)+IMT compared to IMT alone, by 65% for patients treated with SRS+anti-PD1 and by 59% for patients treated with SRS+anti-CTLA4 and/or anti-PD1 (HR 0.41, 95%CI 0.31-0.54) compared to SRS alone. Four studies compared SRS+anti-CTLA4 with SRS+anti-PD1, showing a 42% reduction in risk of death with SRS+anti-PD1 treatment. Combined treatment with SRS+TT showed a 59% reduction in risk compared to SRS alone.
Conclusion: The systematic review suggests a substantial survival benefit for combining SRS with IMT or TT for patients with melanoma brain metastases.
Critical Reviews in Oncology/Hematology , article en libre accès, 2024